Gilead Sciences, Inc. (NEO:GILD)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CAD 207.45 billion. The enterprise value is 229.16 billion.

Market Cap	207.45B
Enterprise Value	229.16B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.36%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.36 and the forward PE ratio is 14.25.

PE Ratio	18.36
Forward PE	14.25
PS Ratio	5.12
PB Ratio	6.94
P/TBV Ratio	n/a
P/FCF Ratio	16.26
P/OCF Ratio	15.41
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.53, with an EV/FCF ratio of 17.96.

EV / Earnings	20.29
EV / Sales	5.60
EV / EBITDA	11.53
EV / EBIT	14.54
EV / FCF	17.96

Financial Position

The company has a current ratio of 1.53, with a Debt / Equity ratio of 1.15.

Current Ratio	1.53
Quick Ratio	1.17
Debt / Equity	1.15
Debt / EBITDA	1.75
Debt / FCF	2.70
Interest Coverage	11.00

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 15.93%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.38%
Return on Invested Capital (ROIC)	15.93%
Return on Capital Employed (ROCE)	24.22%
Revenue Per Employee	2.30M
Profits Per Employee	641,837
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	1.98

Taxes

In the past 12 months, Gilead Sciences has paid 2.47 billion in taxes.

Income Tax	2.47B
Effective Tax Rate	17.96%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	23.95
200-Day Moving Average	n/a
Relative Strength Index (RSI)	46.89
Average Volume (20 Days)	5,324

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.24

Income Statement

In the last 12 months, Gilead Sciences had revenue of CAD 40.51 billion and earned 11.30 billion in profits. Earnings per share was 8.95.

Revenue	40.51B
Gross Profit	31.89B
Operating Income	15.60B
Pretax Income	13.77B
Net Income	11.30B
EBITDA	19.45B
EBIT	15.60B
Earnings Per Share (EPS)	8.95

Balance Sheet

The company has 13.03 billion in cash and 34.52 billion in debt, giving a net cash position of -21.49 billion.

Cash & Cash Equivalents	13.03B
Total Debt	34.52B
Net Cash	-21.49B
Net Cash Per Share	n/a
Equity (Book Value)	29.89B
Book Value Per Share	24.06
Working Capital	9.11B

Cash Flow

In the last 12 months, operating cash flow was 13.47 billion and capital expenditures -703.41 million, giving a free cash flow of 12.76 billion.

Operating Cash Flow	13.47B
Capital Expenditures	-703.41M
Free Cash Flow	12.76B
FCF Per Share	n/a

Margins

Gross margin is 78.72%, with operating and profit margins of 38.50% and 27.88%.

Gross Margin	78.72%
Operating Margin	38.50%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.01%
EBIT Margin	38.50%
FCF Margin	31.50%

Dividends & Yields

Gilead Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	48.31%
Buyback Yield	-1.02%
Shareholder Yield	-1.02%
Earnings Yield	5.45%
FCF Yield	6.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7